Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | STTK |
---|---|---|
09:32 ET | 4843 | 7.19 |
09:34 ET | 348 | 7.26 |
09:36 ET | 200 | 7.36 |
09:41 ET | 334 | 7.2247 |
09:43 ET | 100 | 7.34 |
09:48 ET | 200 | 7.35 |
09:52 ET | 1889 | 7.39 |
09:54 ET | 613 | 7.4 |
09:57 ET | 100 | 7.31 |
10:08 ET | 100 | 7.35 |
10:12 ET | 100 | 7.35 |
10:14 ET | 100 | 7.36 |
10:15 ET | 400 | 7.31 |
10:30 ET | 698 | 7.35 |
10:32 ET | 260 | 7.346 |
10:35 ET | 100 | 7.41 |
10:44 ET | 200 | 7.42 |
10:51 ET | 593 | 7.335 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Shattuck Labs Inc | 350.9M | -3.8x | --- |
Tourmaline Bio Inc | 353.2M | -2.5x | --- |
Anavex Life Sciences Corp | 343.6M | -8.0x | --- |
Nautilus Biotechnology Inc | 343.2M | -5.1x | --- |
Aura Biosciences Inc | 364.1M | -4.1x | --- |
Ventyx Biosciences Inc | 337.0M | -1.0x | --- |
Shattuck Labs, Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRPa macrophage checkpoint interaction and activate the CD40 costimulatory receptor to induce an antitumor immune response. It is conducting a Phase IA/B clinical trial in patients with acute myeloid leukemia (AML) and HR-MDS. It has completed the Phase IA dose-escalation portion of this clinical trial and are enrolling patients in the Phase IB expansion cohorts evaluating SL-172154 in combination with azacitidine in frontline HR-MDS or frontline TP53 mutant (TP53m) AML. It has developed the ARC platform to address the need for a single therapeutic that consolidates multiple immune functions.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $350.9M |
---|---|
Revenue (TTM) | $2.7M |
Shares Outstanding | 47.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.86 |
EPS | $-1.93 |
Book Value | $3.06 |
P/E Ratio | -3.8x |
Price/Sales (TTM) | 129.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -3,327.44% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.